TABLE 3.
Univariate analysis of prognostic factors associated with overall survival of patients with nasopharyngeal carcinoma stratified by SHP-1 expression
| SHP-OR (95% CI) | P | SHP+OR (95% CI) | P | |
|---|---|---|---|---|
| Gender | ||||
| Male | Ref | Ref | ||
| Female | 0.03(0–551.31) | 0.489 | 0.31(0.07–1.37) | 0.121 |
| Age (years) | ||||
| <60 | Ref | Ref | ||
| ≥60 | 1.3(0.13–12.48) | 0.822 | 1.08(0.31–3.84) | 0.901 |
| ECOG | ||||
| 0∼1 | Ref | Ref | ||
| ≥2 | 6.15(0.64–59.51) | 0.117 | 2.28(0.3–17.36) | 0.426 |
| Histology type | ||||
| Type 1, 2.1 | Ref | Ref | ||
| Type 2.2 | 0.15(0.02–1.09) | 0.060 | 0.7(0.2–2.49) | 0.584 |
| T stage | ||||
| T1–T2 | Ref | Ref | ||
| T3–T4 | 0.93(0.13–6.58) | 0.938 | 2.46(0.84–7.2) | 0.100 |
| N stage | ||||
| N0–N1 | Ref | Ref | ||
| N2–N3 | 0.66(0.09–4.73) | 0.683 | 1.84(0.58–5.78) | 0.299 |
| Clinical stage | ||||
| I–II | Ref | Ref | ||
| III–IV | 1(0.1–9.6) | 0.998 | 36.99(0.38–3588.19) | 0.122 |
| RT technique | ||||
| 2D–CRT | Ref | Ref | ||
| IMRT | 1.16(0.16–8.27) | 0.879 | 1.95(0.67–5.71) | 0.224 |
| Chemotherapy | ||||
| New Adjuvant | 5.9(0.61–56.96) | 0.125 | 1.12(0.4–3.13) | 0.836 |
| Concurrent | 1.62(0.23–11.48) | 0.631 | 2(0.73–5.52) | 0.180 |
| Adjuvant | 0.75(0.11–5.36) | 0.778 | 0.55(0.2–1.52) | 0.251 |
OR = Odds ratio; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; RT = radiotherapy; 2D-CRT = 2-dimensional conventional radiotherapy; IMRT = intensity-modulated radiotherapy